Gina S. Ogilvie (Canada)

University of British Columbia Faculty of Medicine

Dr. Ogilvie is a Professor at the University of British Columbia; Senior Scientist at the BC Centre for Disease Control; Canada Research Chair in Global Control of HPV related diseases and cancer and Associate Director of the Women's Health Research Institute. During her career, Dr. Ogilvie has worked in the field of STI prevention and control and leads trials both in Canada and globally with an implementation sciences focus on primary and secondary prevention of HPV related cancers.

Presenter of 1 Presentation

Conference Calendar

Workshop 3: Communications Issues in Optimizing HPV Prevention Strategies Hall B

Engaging community in HPV Prevention Program planning: What do patients and providers say about optimal program design (ID 89)

Session Date

07/20/2020

Session Time

13:30 - 14:55

Room

Hall B

Session Type

Public Health

Session Name

Workshop 3: Communications Issues in Optimizing HPV Prevention Strategies

Lecture Time

14:13 - 14:33

Presenter

Gina S. Ogilvie (Canada)

Authors

Gina S. Ogilvie (Canada)

Moderator of 1 Session

Conference Calendar

Public Health Oral Session

01080 - Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening (ID 57)

Session Type

Public Health Oral Session

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"PREDICTED IMPACT OF HPV VACCINATION AND PRIMARY HPV SCREENING ON ADVERSE PREGNANCY OUTCOMES IN AUSTRALIA 2005-2070: MODELLING IN A HIGH INCOME, HIGH VACCINATION COVERAGE COUNTRY \u003Csmall\u003E(ID 710)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":710,"presentation":"PREDICTED IMPACT OF HPV VACCINATION AND PRIMARY HPV SCREENING ON ADVERSE PREGNANCY OUTCOMES IN AUSTRALIA 2005-2070: MODELLING IN A HIGH INCOME, HIGH VACCINATION COVERAGE COUNTRY \u003Csmall\u003E(ID 710)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Susan E. Yuill (Australia)","photo":""},"playlist":[{"name":"PREDICTED IMPACT OF HPV VACCINATION AND PRIMARY HPV SCREENING ON ADVERSE PREGNANCY OUTCOMES IN AUSTR","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200618-045318_Susan-Yuil_1920x1080-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200618-045318_Susan-Yuil_1920x1080-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/79E106E8.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200618-045318_Susan-Yuil_1920x1080-0.vtt"}]},{"name":"EFFECT OF HPV VACCINATION ON CERVICAL LESIONS IN OPPORTUNISTIC CERVICAL SCREENING AMONG YOUNG WOMEN IN THE NETHERLANDS \u003Csmall\u003E(ID 816)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":816,"presentation":"EFFECT OF HPV VACCINATION ON CERVICAL LESIONS IN OPPORTUNISTIC CERVICAL SCREENING AMONG YOUNG WOMEN IN THE NETHERLANDS \u003Csmall\u003E(ID 816)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Tessa Schurink-van 't Klooster (Netherlands)","photo":""},"playlist":[{"name":"EFFECT OF HPV VACCINATION ON CERVICAL LESIONS IN OPPORTUNISTIC CERVICAL SCREENING AMONG YOUNG WOMEN ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/816.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/816.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/8AA51430.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/816.vtt"}]},{"name":"REDUCTION IN CIN3+ AT SECOND AND SUBSEQUENT SCREENS IN WOMEN IMMUNISED WITH CERVARIX\u00ae \u003Csmall\u003E(ID 1484)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1484,"presentation":"REDUCTION IN CIN3+ AT SECOND AND SUBSEQUENT SCREENS IN WOMEN IMMUNISED WITH CERVARIX\u00ae \u003Csmall\u003E(ID 1484)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Timothy Palmer (United Kingdom)","photo":""},"playlist":[{"name":"REDUCTION IN CIN3 AT SECOND AND SUBSEQUENT SCREENS IN WOMEN IMMUNISED WITH CERVARIX","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/1484 - Tim Palmer - IPVC20 - REDUCTION IN CIN3.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/1484 - Tim Palmer - IPVC20 - REDUCTION IN CIN3.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/7F028B19.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/1484 - Tim Palmer - IPVC20 - REDUCTION IN CIN3.vtt"}]},{"name":"A LINKAGE STUDY OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND PAP SMEAR CERVICAL CANCER SCREENING IN FERRARA, ITALY. \u003Csmall\u003E(ID 1162)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1162,"presentation":"A LINKAGE STUDY OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND PAP SMEAR CERVICAL CANCER SCREENING IN FERRARA, ITALY. \u003Csmall\u003E(ID 1162)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Cecilia Acuti Martellucci (Japan)","photo":""},"playlist":[{"name":"A LINKAGE STUDY OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND PAP SMEAR CERVICAL CANCER SCREENING IN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/3 Ready.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/3 Ready.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/7B85D63E.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/3 Ready.vtt"}]},{"name":"USING CANCER REGISTRIES TO ASSESS HPV VACCINE IMPACT ON VULVAR, VAGINAL, AND ANAL PRECANCERS IN FEMALES UNDER 40 YEARS OF AGE, UNITED STATES 2000-2016 \u003Csmall\u003E(ID 1324)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1324,"presentation":"USING CANCER REGISTRIES TO ASSESS HPV VACCINE IMPACT ON VULVAR, VAGINAL, AND ANAL PRECANCERS IN FEMALES UNDER 40 YEARS OF AGE, UNITED STATES 2000-2016 \u003Csmall\u003E(ID 1324)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Jacqueline M. Mix (United States of America)","photo":""},"playlist":[{"name":"USING CANCER REGISTRIES TO ASSESS HPV VACCINE IMPACT ON VULVAR, VAGINAL, AND ANAL PRECANCERS IN FEMA","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/IPVC 20 - P1324 - S1080 - Jacqueline Mix - joined.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/IPVC 20 - P1324 - S1080 - Jacqueline Mix - joined.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/136B36FA.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/IPVC 20 - P1324 - S1080 - Jacqueline Mix - joined.vtt"}]},{"name":"ESTIMATING THE EFFECT OF HPV VACCINATION ON THE LIFETIME RISK OF SCREEN-DETECTED CERVICAL PRECANCER \u003Csmall\u003E(ID 801)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":801,"presentation":"ESTIMATING THE EFFECT OF HPV VACCINATION ON THE LIFETIME RISK OF SCREEN-DETECTED CERVICAL PRECANCER \u003Csmall\u003E(ID 801)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Federica Inturrisi (Netherlands)","photo":""},"playlist":[{"name":"Federica Inturrisi - IPVC20 - 801","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/Federica Inturrisi - IPVC20 - 801.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/Federica Inturrisi - IPVC20 - 801.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/70C5DF1B.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/Federica Inturrisi - IPVC20 - 801.vtt"}]},{"name":"DOES THE GENOTYPE-SPECIFIC CIN2+ RISK IN CERVICAL SCREENING CHANGE IN PARTLY HPV-VACCINATED COHORTS? \u003Csmall\u003E(ID 290)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":290,"presentation":"DOES THE GENOTYPE-SPECIFIC CIN2+ RISK IN CERVICAL SCREENING CHANGE IN PARTLY HPV-VACCINATED COHORTS? \u003Csmall\u003E(ID 290)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Johannes A. Bogaards (Netherlands)","photo":""},"playlist":[{"name":"DOES THE GENOTYPE-SPECIFIC CIN2+ RISK IN CERVICAL SCREENING CHANGE IN PARTLY HPV-VACCINATED COHORTS?","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/Hans Bogaards IPVC20 PRESENTATION id 290.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/Hans Bogaards IPVC20 PRESENTATION id 290.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/A842F5E8.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/Hans Bogaards IPVC20 PRESENTATION id 290.vtt"}]},{"name":"HPV VACCINE EFFECTIVENESS AND CROSS-PROTECTION BY AGE AT VACCINATION, TIMING OF SEXUAL INITIATION IN RELATION TO VACCINATION, AND NUMBER OF DOSES IN A REAL-WORLD SETTING \u003Csmall\u003E(ID 670)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":670,"presentation":"HPV VACCINE EFFECTIVENESS AND CROSS-PROTECTION BY AGE AT VACCINATION, TIMING OF SEXUAL INITIATION IN RELATION TO VACCINATION, AND NUMBER OF DOSES IN A REAL-WORLD SETTING \u003Csmall\u003E(ID 670)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Jessica A. Kahn (United States of America)","photo":""},"playlist":[{"name":"HPV VACCINE EFFECTIVENESS AND CROSS-PROTECTION BY AGE AT VACCINATION, TIMING OF SEXUAL INITIATION IN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200610-145251_Jessica-Ka_1686x768.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200610-145251_Jessica-Ka_1686x768.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/1D2A9290.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200610-145251_Jessica-Ka_1686x768.vtt"}]}]